Emblem Cannabis (EMC)

[howestreetbull]

Initiating Coverage of Emblem Corp. (EMC-TSXV, $3.60, Speculative Buy, PT $5.25): We view EMC as an attractive investment at
current levels given our outlook for cannabis-based product demand, a balance sheet that supports rapid capacity expansion, and
its vertically integrated model led by strong management. The Company is currently completing its Phase 2 expansion that should
triple production capability to 2,100 kg, with commissioning expected by April 2017. We estimate that EMC has another $40M
available to fund additional expansion to support expected demand from the recreational market. The Company’s pharmaceutical
division, led by Mr. John Stewart (former President/CEO of Purdue Pharma Canada and Purdue Pharma USA), is working to
develop cannabinoid-based formulations, which should help drive market expansion.

https://equity.guru/wp-content/uploads/2017/02/Cannabis_Theme_Report.pdf